16+
Major trials tracked
A triple agonist against a dual agonist in metabolic disease
Retatrutide vs tirzepatide: trial pipelines compared
A side-by-side view of the retatrutide and tirzepatide clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for retatrutide and 16+ for tirzepatide. Add up to three more drugs to widen the comparison.
retatrutide (16) vs tirzepatide (16)15 active2018–2032
retatrutidetirzepatide
'18
'20
'22
'24
'26
'28
'30
'32
retatrutide
A Study of LY3437943 in Participants With Type 2 DiabetesP2
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightP2
TRIUMPH-3P3
TRIUMPH-1P3
TRIUMPH-2P3
TRIUMPH-4P3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)P3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)P3
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)P3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)P3
TRIUMPH-5P3
TRIUMPH-6P3
TRIUMPH-7P3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)P3
TRIUMPH-9P3
GZBFP2
tirzepatide
SURPASS-4P3
SYNERGY-NASHP2
SURMOUNT-3P3
SURMOUNT-CNP3
SURPASS-CN-INSP3
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)P3
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityP2
T-RAMP4
STOP KNEE-OAP4
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsP2
SURPASS-T1D-1P3
Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesP3
Multi-Site Trial of Tirzepatide for Smoking CessationP2
AI-LIFE-T2D-OBP4
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or ObeseP2
TOPAZP2
Upcoming readouts
13 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
retatrutideGLP-1 & incretin therapies
13
Phase 3 trials
2
Actively recruiting
Nov 2026
Next phase 3 readout
tirzepatide (Mounjaro / Zepbound)GLP-1 & incretin therapies
16+
Major trials tracked
7
Phase 3 trials
1
Actively recruiting
Nov 2026
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across retatrutide and tirzepatide, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track retatrutide and tirzepatide with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the retatrutide and tirzepatide clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for retatrutide and 16+ for tirzepatide. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.
